Spero Therapeutics, INC Form 4 insider transactions
NASDAQ
Ankit Mahadevia, a director at Spero Therapeutics, sold 5,912 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
NASDAQ
Timothy Keutzer, COO of Spero Therapeutics, sold 2,213 shares of common stock to cover tax withholding obligations related to the vesting of RSUs.
NASDAQ
Sath Shukla, CEO of Spero Therapeutics, sold 2,757 shares of common stock on August 27, 2024, to cover tax withholding obligations related to vesting RSUs.
NASDAQ
Sath Shukla, CEO and President of Spero Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting RSUs.
NASDAQ
Director Milind Deshpande acquired 20,000 shares of Spero Therapeutics common stock on May 29, 2024, in the form of restricted stock units.
NASDAQ
Director Scott Thomas Jackson reports acquisition and disposal of Spero Therapeutics stock, including the grant of restricted stock units.
NASDAQ
Director Patrick V.J.J. Vink acquired 20,000 shares of Spero Therapeutics common stock on May 29, 2024, through restricted stock units.
NASDAQ
Director Ankit Mahadevia reports acquiring 20,000 shares of Spero Therapeutics common stock through restricted stock units.
NASDAQ
Director Kathleen Tregoning acquired 20,000 shares of Spero Therapeutics common stock on May 29, 2024, in the form of restricted stock units.
NASDAQ
Form 4: Spero Therapeutics Director Cynthia Smith Reports Acquisition of 20,000 Shares of Common Stock
Director Cynthia Smith reports acquiring 20,000 shares of Spero Therapeutics common stock on May 29, 2024, bringing her total holdings to 55,000 shares.
NASDAQ
Frank E. Thomas, a director of Spero Therapeutics, acquired 20,000 shares of common stock on May 29, 2024, as part of a restricted stock unit grant.
NASDAQ
Director John C. Pottage Jr. of Spero Therapeutics acquired 20,000 shares of common stock on May 29, 2024, through restricted stock units.